tetano
Editor, Senior Moderator
Arch Toxicol
. 2023 Jul 25.
doi: 10.1007/s00204-023-03549-6. Online ahead of print. Preclinical evaluation of general toxicity and safety pharmacology of a receptor-binding domain-based COVID-19 subunit vaccine in various animal models
Sang-Jin Park[SUP] 1 [/SUP], Min Seong Jang[SUP] 1 [/SUP], Kwang-Hyun Lim[SUP] 1 [/SUP], Joung-Wook Seo[SUP] 1 [/SUP], Wan-Jung Im[SUP] 1 [/SUP], Kang-Hyun Han[SUP] 1 [/SUP], Seong-Eun Kim[SUP] 2 [/SUP], Eunhee Jang[SUP] 2 [/SUP], Danbi Park[SUP] 2 [/SUP], Yong-Bum Kim[SUP] 3 [/SUP]
Affiliations
The coronavirus disease 2019 pandemic has resulted in the introduction of several naïve methods of vaccine development, which have been used to prepare novel viral vectors and mRNA-based vaccines. However, reluctance to receive vaccines owing to the uncertainty regarding their safety is prevalent. Therefore, rigorous safety evaluation of vaccines through preclinical toxicity studies is critical to determine the safety profiles of vaccine candidates. This study aimed to evaluate the toxicity profile of HuVac-19, a subunit vaccine of SARS-CoV-2 utilizing the receptor-binding domain as an antigen, in rats, rabbits, and dogs using single- and repeat-dose study designs. Repeat-dose toxicity studies in rats and rabbits showed transient changes in hematological and serum biochemical parameters in the adjuvant and/or vaccine groups; however, these changes were reversed or potentially reversible after the recovery period. Moreover, temporary reversible changes in absolute and relative organ weights were observed in the prostate of rats and the thymus of rabbits. Gross examination of the injection sites in rats and rabbits treated with the adjuvant- and HuVac-19 showed discoloration and foci, whereas histopathological examination showed granulomatous inflammation, inflammatory cell infiltration, and myofiber degeneration/necrosis. This inflammatory response was local, unassociated with other toxicological changes, and resolved. In a pharmacological safety study, no toxicological or physiological changes associated with HuVac-19 administration were observed. In conclusion, HuVac-19 was not associated with any major systemic adverse effects in the general toxicity and safety pharmacology evaluation, demonstrating that HuVac-19 is a vaccine candidate with sufficient capacity to be used in human clinical trials.
Keywords: Preclinical study; Receptor binding domain; SARS-CoV-2; Subunit vaccine; Toxicity.
. 2023 Jul 25.
doi: 10.1007/s00204-023-03549-6. Online ahead of print. Preclinical evaluation of general toxicity and safety pharmacology of a receptor-binding domain-based COVID-19 subunit vaccine in various animal models
Sang-Jin Park[SUP] 1 [/SUP], Min Seong Jang[SUP] 1 [/SUP], Kwang-Hyun Lim[SUP] 1 [/SUP], Joung-Wook Seo[SUP] 1 [/SUP], Wan-Jung Im[SUP] 1 [/SUP], Kang-Hyun Han[SUP] 1 [/SUP], Seong-Eun Kim[SUP] 2 [/SUP], Eunhee Jang[SUP] 2 [/SUP], Danbi Park[SUP] 2 [/SUP], Yong-Bum Kim[SUP] 3 [/SUP]
Affiliations
- PMID: 37491472
- DOI: 10.1007/s00204-023-03549-6
The coronavirus disease 2019 pandemic has resulted in the introduction of several naïve methods of vaccine development, which have been used to prepare novel viral vectors and mRNA-based vaccines. However, reluctance to receive vaccines owing to the uncertainty regarding their safety is prevalent. Therefore, rigorous safety evaluation of vaccines through preclinical toxicity studies is critical to determine the safety profiles of vaccine candidates. This study aimed to evaluate the toxicity profile of HuVac-19, a subunit vaccine of SARS-CoV-2 utilizing the receptor-binding domain as an antigen, in rats, rabbits, and dogs using single- and repeat-dose study designs. Repeat-dose toxicity studies in rats and rabbits showed transient changes in hematological and serum biochemical parameters in the adjuvant and/or vaccine groups; however, these changes were reversed or potentially reversible after the recovery period. Moreover, temporary reversible changes in absolute and relative organ weights were observed in the prostate of rats and the thymus of rabbits. Gross examination of the injection sites in rats and rabbits treated with the adjuvant- and HuVac-19 showed discoloration and foci, whereas histopathological examination showed granulomatous inflammation, inflammatory cell infiltration, and myofiber degeneration/necrosis. This inflammatory response was local, unassociated with other toxicological changes, and resolved. In a pharmacological safety study, no toxicological or physiological changes associated with HuVac-19 administration were observed. In conclusion, HuVac-19 was not associated with any major systemic adverse effects in the general toxicity and safety pharmacology evaluation, demonstrating that HuVac-19 is a vaccine candidate with sufficient capacity to be used in human clinical trials.
Keywords: Preclinical study; Receptor binding domain; SARS-CoV-2; Subunit vaccine; Toxicity.